Early and severe forms of polycystic kidney disease (PKD) do already manifest during childhood or adolescence. They are characterized by enlarged kidneys and diminished renal function that prenatally may result in Potter’s oligohydramnios sequence. Genetically, various defects can mimic this phenotype. Most common are PKHD1 mutations that lead to autosomal recessive PKD (ARPKD). About the same number of children do carry mutations in the dominant autosomal dominant polycystic kidney disease (ADPKD) genes, PKD1 and less frequent PKD2, often arise de novo or may affect both disease alleles in a recessive mode. Mutations in DZIP1L have been recently described to result in an ARPKD-like phenotype. Likewise, mutations in several other cystogenes can phenocopy early and severe PKD. Early and reliable prenatal diagnosis for which there is a strong demand in ARPKD and related diseases is feasible only by genetics. A comprehensive knowledge of disease-causing genes is essential for the correct diagnosis and parental counselling. The increasing number of genes that need to be considered benefits from the advances of next generation sequencing and allows the simultaneous analysis of all genes of interest in a single test, which is now the mainstay for genetic diagnosis. Interpretation of data is challenging and requires expert knowledge in data handling, bioinformatics and clinical genetics.

Keywords:
Autosomal recessive polycystic kidney disease, PKHD1, DZIP1L, Autosomal dominant polycystic kidney disease , Polycystic kidney disease 1/2, Ciliopathies, HNF1β/ TCF2, Nephronophthisis, Bardet-Biedl syndrome, Joubert syndrome and related disorders
1.
Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, et al: Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr 2014; 165: 611–617.
2.
Adeva M, El-Youssef M, Rossetti S: Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 2006: 1–21.
3.
Bergmann C, Senderek J, Windelen E: Clinical consequences of PKHD1 mutations in 164 patients with autosomal recessive polycystic kidney disease (ARPKD). Kidney Int 2005: 829–848.
4.
Avni FE, Guissard G, Hall M, Janssen F, et al: Hereditary polycystic kidney diseases in children: changing sonographic patterns through childhood. Pediatr Radiol 2002; 32: 169–174.
5.
Drenth JP, Chrispijn M, Bergmann C: Congenital fibrocystic liver diseases. Best Pract Res Clin Gastroenterol 2010; 24: 573–584.
6.
Turkbey B, Ocak I, Daryanani K: Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol 2009: 100–111.
7.
Desmet VJ: Ludwig symposium on biliary disorders – part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998; 73: 80–89.
8.
Guay-Woodford LM, Desmond RA: Autosomal recessive polycystic kidney disease: the clinical experience in north america. Pediatrics 2003; 111: 1072–1080.
9.
Telega G, Cronin D, Avner ED: New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications. Pediatr Transplant 2013; 17: 328–335.
10.
Rossetti S, Torra R, Coto E, Consugar M, et al: A complete mutation screen of pkhd1 in autosomal recessive polycystic kidney pedigrees. Kidney Int 2003; 64: 391–403.
11.
Gallagher AR, Esquivel EL, Briere TS, Tian X, et al: Biliary and pancreatic dysgenesis in mice harboring a mutation in PKHD1. Am J Pathol 2008; 172: 417–429.
12.
Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, et al: Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 2007; 16: 1940–1950.
13.
Moser M, Matthiesen S, Kirfel J: A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2005: 1113–1121.
14.
Woollard JR, Punyashtiti R, Richardson S, Masyuk TV, et al: A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 2007; 72: 328–336.
15.
Follit JA, Li L, Vucica Y, Pazour GJ: The cytoplasmic tail of fibrocystin contains a ciliary targeting sequence. J Cell Biol 2010; 188: 21–28.
16.
Onuchic LF, Furu L, Nagasawa Y: Pkhd1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002: 1305–1317.
17.
Harris PC, Torres VE: Polycystic kidney disease. Annu Rev Med 2009: 321–337.
18.
Hiesberger T, Gourley E, Erickson A, Koulen P, et al: Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular ca2+ and activation of protein kinase C. J Biol Chem 2006; 281: 34357–34364.
19.
Kaimori JY, Nagasawa Y, Menezes LF, Garcia-Gonzalez MA, et al: Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum Mol Genet 2007; 16: 942–956.
20.
Bergmann C, Senderek J, Schneider F, Dornia C, et al: PKHD1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 2004; 23: 487–495.
21.
Bergmann C: Autosomal Recessive Polycystic Kidney Disease. Oxford University Press, Oxford, 2014.
22.
Boddu R, Yang C, O’Connor AK, Hendrickson RC, et al: Intragenic motifs regulate the transcriptional complexity of PKHD1/PKHD1. J Mol Med (Berl) 2014; 92: 1045–1056.
23.
Frank V, Zerres K, Bergmann C: Transcriptional complexity in autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 2014; 9: 1729–1736.
24.
Lu H, Galeano MCR, Ott E, Kaeslin G, et al: Mutations in dzip1l, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet 2017; 49: 1025–1034.
25.
Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007: 1287–1301.
26.
Bergmann C: Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front Pediatr 2018; 5: 221.
27.
Xu HW, Yu SQ, Mei CL, Li MH: Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011; 42: 204–206.
28.
Pirson Y, Chauveau D, Torres V: Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002; 13: 269–276.
29.
Irazabal MV, Huston J, 3rd, Kubly V, Rossetti S, et al.: Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1274–1285.
30.
Eisenberger T, Decker C, Hiersche M, Hamann RC, et al: An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease. PLoS One 2015; 10: e0116680.
31.
Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, et al: Mutations in ganab, encoding the glucosidase iialpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 2016; 98: 1193–1207.
32.
Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009: 149–168.
33.
Bergmann C, von Bothmer J, Ortiz Bruchle N, Venghaus A, et al: Mutations in multiple pkd genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 2011; 22: 2047–2056.
34.
Kim I, Fu Y, Hui K, Moeckel G, et al: Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol 2008; 19: 455–468.
35.
Wang S, Zhang J, Nauli SM, Li X, et al: Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007; 27: 3241–3252.
36.
Wu Y, Dai XQ, Li Q, Chen CX, et al: Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet 2006; 15: 3280–3292.
37.
Harris PC, Bae KT, Rossetti S, Torres VE, et al: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006; 17: 3013–3019.
38.
Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, et al: Type of pkd1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013; 24: 1006–1013.
39.
Fedeles SV, Tian X, Gallagher AR, Mitobe M, et al: A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet 2011; 43: 639–647.
40.
Cornec-Le Gall E, Torres VE, Harris PC: Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 2018; 29: 13–23.
41.
Kleffmann J, Frank V, Ferbert A, Bergmann C: Dosage-sensitive network in polycystic kidney and liver disease: multiple mutations cause severe hepatic and neurological complications. J Hepatol 2012; 57: 476–477.
42.
Roth C, Kleffmann J, Bergmann C, Deinsberger W, et al: Ruptured cerebral aneurysm and acute bilateral carotid artery dissection in a patient with polycystic kidney disease and polycystic liver disease. Cerebrovascular diseases 2013; 35: 590–591.
43.
Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345–1356.
44.
Shepherd CW, Gomez MR, Lie JT, Crowson CS: Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66: 792–796.
45.
Shillingford J, Murcia N, Larson C, Low S, et al: The mtor pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006 5466–5471.
46.
Decramer S, Parant O, Beaufils S, Clauin S, et al: Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol 2007; 18: 923–933.
47.
Hiesberger T, Bai Y, Shao X, McNally BT, et al: Mutation of hepatocyte nuclear factor-1beta inhibits pkhd1 gene expression and produces renal cysts in mice. J Clin Invest 2004; 113: 814–825.
48.
Aamodt K, Abelev B, Abrahantes Quintana A, Adamova D, et al: Higher harmonic anisotropic flow measurements of charged particles in Pb-Pb collisions at sqrt(s(nn))=2.76 tev. Phys Rev Lett 2011; 107: 032301.
49.
Moreno-De-Luca D, Consortium S, Mulle JG, Simons Simplex Collection Genetics C, et al.: Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet 2010; 87: 618–630.
50.
Nagamani SC, Erez A, Shen J, Li C, et al: Clinical spectrum associated with recurrent genomic rearrangements in chromosome 17q12. Eur J Hum Genet 2010; 18: 278–284.
51.
Hoff S, Halbritter J, Epting D, Frank V, et al: ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. Nat Genet 2013; 45: 951–956.
52.
Hildebrandt F, Zhou W: Nephronophthisis-associated ciliopathies. J Am Soc Nephrol 2007; 18: 1855–1871.
53.
Salomon R, Saunier S, Niaudet P: Nephronophthisis. Pediatr Nephrol 2009; 24: 2333–2344.
54.
Omran H: Nephronophthis and medullary cystic kidney disease; in Geary DF, Schaefer F (eds): Comprehensive Pediatric Nephrology. Elsevier, 2008, pp 143–154.
55.
Bergmann C, Fliegauf M, Bruchle NO, Frank V, et al: Loss of nephrocystin-3 function can cause embryonic lethality, meckel-gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet 2008; 82: 959–970.
56.
Eckardt KU, Alper SL, Antignac C, Bleyer AJ, et al: Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management – a kdigo consensus report. Kidney Int 2015; 88: 676–683.
57.
Parisi MA: Clinical and molecular features of Joubert syndrome and related disorders. Am J Med Genet C Semin Med Genet 2009; 151C: 326–340.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.